expression products and compositions comprising said products.

Group 4, claims 12-16, drawn to modulators of MK2/protein interactions and assay utilizing said modulators.

Group 5, claims 17-18, drawn to antibodies which bind MK2/STS or inhibit their interaction with STS.

Group 6, claims 17-18, drawn to antibodies which bind MK2/Shc protein or inhibit MK2 interaction with Shc.

Group 7, claims 17-18, drawn to antibodies which bind MK2/HPH2 Protein complex or inhibit MK2 interaction with HPH2.

Group 8, claim 19, drawn to a method of modulating formation of MK2/STS utilizing modulators.

Group 9, claim 19, drawn to a method of modulating formation of MK2/HPH2 utilizing modulators.

Group 10, claim 19, drawn to a method of modulating formation of MK2/Shc utilizing modulators.

Group 11, claims 21-25, 28-31, drawn to a method of drug screening comprising utilizing MK2/STS protein complex.

Group 12, claims 21-25, 26, 28-31, drawn to a method of drug screening comprising utilizing MK2/Shc protein complex.

Group 13, claims 21-24, 27-31, drawn to a method of drug screening comprising utilizing MK2/HPH2 protein complex.

Group 14, claims 32-33, drawn to a method of modulating inflammation utilizing DNA encoding MK2/STS protein complex.

Group 15, claims 32-33, drawn to a method of modulating inflammation utilizing DNA encoding MK2/Shc protein complex.

Group 16, claims 32-33, drawn to a method of modulating inflammation utilizing DNA encoding MK2/HPH2 protein complex.

Group 17, claims 34-41, drawn to method of treating inflammation utilizing an agent that blocks MK2 activity or blocks its interaction with other proteins.

Group 18, claim 42, drawn to method of modulating inflammation in a tissue comprising contacting said tissue with an MK2 binding agent.

Group 19, claims 43-46, drawn to a method of treatment comprising administering an agent that interacts with MK2 activity or with an MK2/protein complex.

Group 20, claims 47-48, drawn to a method of expressing DNA encoding modulators of MK2 or MK2/STS complex formation in a cell.

Group 21, claims 47-48, drawn to a method of expressing DNA encoding modulators of MK2 or MK2/Shc complex formation in a cell.

Group 22, claims 47-48, drawn to a method of expressing DNA encoding modulators of MK2 or MK2/HPH2 complex formation in a cell.

Group 23, claims 49-54, drawn to a method of detecting presence or absence of MK2 in sample utilizing modulators of MK2 or MK2/STS complex.

Group 24, claims 49-54, drawn to a method of detecting presence or absence of MK2 in sample utilizing modulators of MK2 or MK2/Shc complex.

Group 25, claims 49-54, drawn to a method of detecting presence or absence of MK2 in sample utilizing modulators of MK2 or MK2/HPH2 complex and kits comprising said modulators.

Applicants provisionally elect Group 4, directed to claims 12-16 with traverse. The Examiner has failed to show that searching all of the groups would constitute an undue burden on the Examiner. All of the groups recite the novel MK2 complex disclosed in the application and a search of each of the groups would overlap.

Therefore, while Applicants elect group 4, Applicants request that the Examiner consider all of the claims. These claims encompass an assay for determining whether a test compound inhibits or promotes complex formation, a method for determining whether a test compound affects MK2 activity, and a screening assay to identify compounds that inhibit or promote complex formation.

Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: November 3, 2006

By: James P. Kastenmayer
James P. Kastenmayer
Reg. No. 51,862